Kilitch Drugs (India) Ltd's Q4FY25 Quarter Results
- 20 May 2025
Result Summary
- Kilitch Drugs (India) Ltd reported a 21.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a decline of 2.6%.
- Its expenses for the quarter were down by 19.4% QoQ and 3.4% YoY.
- The net profit decreased 34.4% QoQ and increased 26.9% YoY.
- The earnings per share (EPS) of Kilitch Drugs (India) Ltd stood at 2.2 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 45.29 | 57.89 | 46.50 | -21.8% | -2.6% |
Total Expenses | 39.99 | 49.64 | 41.38 | -19.4% | -3.4% |
Profit Before Tax | 5.30 | 8.25 | 5.11 | -35.8% | 3.7% |
Tax | 1.62 | 2.64 | 2.21 | -38.6% | -26.7% |
Profit After Tax | 3.68 | 5.61 | 2.90 | -34.4% | 26.9% |
Earnings Per Share | 2.20 | 3.70 | 2.30 | -40.5% | -4.3% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Kilitch Drugs (India) Ltd is a pharmaceutical company involved in the manufacturing and distribution of a wide range of pharmaceutical products. The company operates within the pharmaceutical industry, focusing on producing various formulations, including tablets, capsules, injectables, and other related products. The company is known for its commitment to quality and compliance with international standards in drug manufacturing. Recent developments within Kilitch Drugs may include expansion of product lines, partnerships with other pharmaceutical firms, or strategic initiatives to enhance market presence, although specific details regarding such developments are not provided here.
Revenue
In Q4FY25, Kilitch Drugs (India) Ltd reported a total income of ₹45.29 crores, a decrease from ₹57.89 crores in Q3FY25, representing a quarter-over-quarter (QoQ) decline of 21.8%. Compared to the same quarter in the previous year (Q4FY24), the total income decreased by 2.6% from ₹46.50 crores. The company's revenue performance over the quarter and year indicates fluctuations in sales, which may correspond to various market dynamics or operational factors. These changes in revenue can be attributed to the company's sales strategy, market demand, or other external economic conditions affecting the pharmaceutical sector.
Profitability
The company's profit before tax in Q4FY25 was ₹5.30 crores, marking a significant decline of 35.8% from ₹8.25 crores in Q3FY25, but it demonstrated a modest increase of 3.7% from ₹5.11 crores in Q4FY24. After accounting for taxes, Kilitch Drugs reported a profit after tax of ₹3.68 crores in Q4FY25, which is 34.4% lower than the previous quarter's ₹5.61 crores but 26.9% higher than the ₹2.90 crores reported in Q4FY24. The tax expense for the quarter was ₹1.62 crores, which is a reduction from both the previous quarter and the same quarter last year. The earnings per share decreased to ₹2.20 from ₹3.70 in Q3FY25 and decreased slightly from ₹2.30 in Q4FY24.
Operating Metrics
The analysis of operating metrics reveals that total expenses for Kilitch Drugs in Q4FY25 amounted to ₹39.99 crores, showing a decrease of 19.4% from Q3FY25 when expenses were ₹49.64 crores. Compared to Q4FY24, expenses decreased by 3.4% from ₹41.38 crores. These figures suggest changes in the company's cost structure, which may include reductions in operational costs or variances in input costs. The company's operational efficiency can be assessed through these expense figures, which reflect its ability to manage costs effectively in relation to its revenue generation over different quarters.